Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting.
Journal: Future oncology (London, England)
Published: July 03, 2026
Developing and evaluating definitions of real-world clinical endpoints for patients with early-stage triple-negative breast cancer using a United States of America secondary database.
Journal: ESMO real world data and digital oncology
Published: April 20, 2026
ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Journal: Annals of surgical oncology
Published: March 12, 2026
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.
Journal: NPJ breast cancer
Published: December 15, 2025
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Journal: Annals of surgical oncology
Published: October 03, 2025
Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer.
Journal: Future oncology (London, England)
Published: April 10, 2024
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study.
Journal: Journal of the National Cancer Institute
Published: March 20, 2024
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 30, 2023
Association between event-free survival and overall survival in early-stage triple-negative breast cancer.
Journal: Future oncology (London, England)
Published: August 21, 2023
Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
Journal: BMC cancer
Published: April 07, 2023
Last Updated: 09/26/2026